Serena Marchio'

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1539707/publications.pdf Version: 2024-02-01



SEDENA MARCHIO'

#	Article	IF	CITATIONS
1	Paclitaxel Restores Sensitivity to Chemotherapy in Preclinical Models of Multidrug-Resistant Intrahepatic Cholangiocarcinoma. Frontiers in Oncology, 2022, 12, 771418.	2.8	4
2	Nanoparticles as Physically- and Biochemically-Tuned Drug Formulations for Cancers Therapy. Cancers, 2022, 14, 2473.	3.7	7
3	Bacteriophages as Therapeutic and Diagnostic Vehicles in Cancer. Pharmaceuticals, 2021, 14, 161.	3.8	30
4	Phage Display-Based Nanotechnology Applications in Cancer Immunotherapy. Molecules, 2020, 25, 843.	3.8	32
5	Emerging Pharmacologic Targets in Cerebral Cavernous Malformation and Potential Strategies to Alter the Natural History of a Difficult Disease. JAMA Neurology, 2019, 76, 492.	9.0	36
6	A Functional Idiotype/Anti-Idiotype Network Is Active in Genetically Gluten-Intolerant Individuals Negative for Both Celiac Disease–Related Intestinal Damage and Serum Autoantibodies. Journal of Immunology, 2019, 202, 1079-1087.	0.8	4
7	Targeted nanomedicines for applications in preclinical cancer models. Bulletin of Russian State Medical University, 2019, , 5-13.	0.2	0
8	Anti-GRP78 autoantibodies induce endothelial cell activation and accelerate the development of atherosclerotic lesions. JCI Insight, 2018, 3, .	5.0	31
9	An antivascular vaccine to boost self-immunity and strike the tumor. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E3164-E3165.	7.1	1
10	Interaction between Tumor Cell Surface Receptor RAGE and Proteinase 3 Mediates Prostate Cancer Metastasis to Bone. Cancer Research, 2017, 77, 3144-3150.	0.9	31
11	Autoantibodies against the cell surface–associated chaperone GRP78 stimulate tumor growth via tissue factor. Journal of Biological Chemistry, 2017, 292, 21180-21192.	3.4	17
12	Going viral? Linking the etiology of human prostate cancer to the <i> <scp>PCA</scp> 3 </i> long noncoding <scp>RNA</scp> and oncogenic viruses. EMBO Molecular Medicine, 2017, 9, 1327-1330.	6.9	10
13	BMTP-11 is active in preclinical models of human osteosarcoma and a candidate targeted drug for clinical translation. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 8065-8070.	7.1	26
14	Intracellular targeting of annexin A2 inhibits tumor cell adhesion, migration, and in vivo grafting. Scientific Reports, 2017, 7, 4243.	3.3	38
15	Brain endothelial cellâ€ŧargeted gene therapy of neurovascular disorders. EMBO Molecular Medicine, 2016, 8, 592-594.	6.9	9
16	BCAM and LAMA5 Mediate the Recognition between Tumor Cells and the Endothelium in the Metastatic Spreading of KRAS-Mutant Colorectal Cancer. Clinical Cancer Research, 2016, 22, 4923-4933.	7.0	50
17	Towards a transcriptome-based theranostic platform for unfavorable breast cancer phenotypes. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 12780-12785.	7.1	31
18	Targeted molecular-genetic imaging and ligand-directed therapy in aggressive variant prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 12786-12791.	7.1	39

SERENA MARCHIO'

#	Article	IF	CITATIONS
19	Interleukin-11 Receptor Is a Candidate Target for Ligand-Directed Therapy in Lung Cancer. American Journal of Pathology, 2016, 186, 2162-2170.	3.8	18
20	Ligand-targeted theranostic nanomedicines against cancer. Journal of Controlled Release, 2016, 240, 267-286.	9.9	154
21	Self-targeting of TNF-releasing cancer cells in preclinical models of primary and metastatic tumors. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 2223-2228.	7.1	35
22	Neuroblastoma-targeted nanocarriers improve drug delivery and penetration, delay tumor growth and abrogate metastatic diffusion. Biomaterials, 2015, 68, 89-99.	11.4	36
23	PRUNE2 is a human prostate cancer suppressor regulated by the intronic long noncoding RNA <i>PCA3</i> . Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 8403-8408.	7.1	226
24	The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma. BMC Cancer, 2015, 15, 374.	2.6	24
25	Synchronous down-modulation of miR-17 family members is an early causative event in the retinal angiogenic switch. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 3770-3775.	7.1	39
26	The Neuronal Pentraxin-2 Pathway Is an Unrecognized Target in Human Neuroblastoma, Which Also Offers Prognostic Value in Patients. Cancer Research, 2015, 75, 4265-4271.	0.9	20
27	Anti-cancer effect and gene modulation of ET-743 in human biliary tract carcinoma preclinical models. BMC Cancer, 2014, 14, 918.	2.6	8
28	Angiopoietin-like 7, a novel pro-angiogenetic factor over-expressed in cancer. Angiogenesis, 2014, 17, 881-896.	7.2	55
29	The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 Upregulation in Osteosarcoma Preclinical Models. Clinical Cancer Research, 2013, 19, 2117-2131.	7.0	96
30	Novel phage display-derived neuroblastoma-targeting peptides potentiate the effect of drug nanocarriers in preclinical settings. Journal of Controlled Release, 2013, 170, 233-241.	9.9	41
31	A peptide from the extracellular region of the synaptic protein α Neurexin stimulates angiogenesis and the vascular specific tyrosine kinase Tie2. Biochemical and Biophysical Research Communications, 2013, 432, 574-579.	2.1	9
32	The V1/V2 loop of HIVâ€1 gp120 is necessary for Tat binding and consequent modulation of virus entry. FEBS Letters, 2013, 587, 2943-2951.	2.8	8
33	Emerging lymphae for the fountain of life. EMBO Journal, 2013, 32, 609-611.	7.8	6
34	Luminescent Silica Nanoparticles for Cancer Diagnosis. Current Medicinal Chemistry, 2013, 20, 2195-2211.	2.4	70
35	Antitumor Activity of Src Inhibitor Saracatinib (AZD-0530) in Preclinical Models of Biliary Tract Carcinomas. Molecular Cancer Therapeutics, 2012, 11, 1528-1538.	4.1	14
36	A complex of α ₆ integrin and Eâ€cadherin drives liver metastasis of colorectal cancer cells through hepatic angiopoietinâ€like 6. EMBO Molecular Medicine, 2012, 4, 1156-1175.	6.9	44

SERENA MARCHIO'

#	Article	IF	CITATIONS
37	IL-12-dependent innate immunity arrests endothelial cells in G0–G1 phase by a p21Cip1/Waf1-mediated mechanism. Angiogenesis, 2012, 15, 713-725.	7.2	5
38	Targeted dual-color silica nanoparticles provide univocal identification of micrometastases in preclinical models of colorectal cancer. International Journal of Nanomedicine, 2012, 7, 4797.	6.7	31
39	SERS active Ag nanoparticles in mesoporous silicon: detection of organic molecules and peptide–antibody assays. Journal of Raman Spectroscopy, 2012, 43, 730-736.	2.5	70
40	Combined targeting of perivascular and endothelial tumor cells enhances anti-tumor efficacy of liposomal chemotherapy in neuroblastoma. Journal of Controlled Release, 2010, 145, 66-73.	9.9	78
41	Targeting the extracellular signature of metastatic colorectal cancers. Expert Opinion on Therapeutic Targets, 2009, 13, 363-379.	3.4	6
42	A new computational approach to analyze human protein complexes and predict novel protein interactions. Genome Biology, 2007, 8, R256.	9.6	8
43	Cell surface-associated Tat modulates HIV-1 infection and spreading through a specific interaction with gp120 viral envelope protein. Blood, 2005, 105, 2802-2811.	1.4	44
44	Identification of CD36 molecular features required for its in vitro angiostatic activity. FASEB Journal, 2005, 19, 1713-1715.	0.5	73
45	Aminopeptidase A is a functional target in angiogenic blood vessels. Cancer Cell, 2004, 5, 151-162.	16.8	132
46	c-fos-induced growth factor/vascular endothelial growth factor D induces angiogenesis in vivo and in vitro. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 9671-9676.	7.1	240
47	Vascular Endothelial Growth Factor-C Stimulates the Migration and Proliferation of Kaposi's Sarcoma Cells. Journal of Biological Chemistry, 1999, 274, 27617-27622.	3.4	86
48	Overexpression of the RON gene in human breast carcinoma. Oncogene, 1998, 16, 2927-2933.	5.9	190